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Negative costimulatory molecules, acting through so-called inhibitory pathways, play a cru-
cial role in the control of T cell responses. This negative “second signal” opposes T cell
receptor activation and leads to downregulation ofT cell proliferation and promotes antigen
speciﬁc tolerance. Much interest has focused upon these pathways in recent years as a
method to control detrimental alloresponses and promote allograft tolerance. However,
recent experimental data highlights the complexity of negative costimulatory pathways in
alloimmunity. Varying effects are observed from molecules expressed on donor and recip-
ient tissues and also depending upon the activation status of immune cells involved.There
appears to be signiﬁcant overlap and redundancy within these systems, rendering this a
challenging area to understand and exploit therapeutically. In this article, we will review the
literature at the current time regarding the major negative costimulation pathways includ-
ing CTLA-4:B7, PD-1:PD-L1/PD-L2 and PD-L1:B7-1, B7-H3, B7-H4, HVEM:BTLA/CD160,
and TIM-3:Galectin-9. We aim to outline the role of these pathways in alloimmunity and
discuss their potential applications for tolerance induction in transplantation.
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INTRODUCTION
CD4+ T cells are initially stimulated through the T cell receptor
(TCR), by the recognition of antigen presented with major his-
tocompatibility complex (MHC) Class II molecules. Full T cell
activation requires a “second signal” or binding of a costimulatory
molecule at the time of TCR ligation. The most important costim-
ulatory molecule is CD28 and mice deﬁcient in CD28 or one of
its ligands (B7-1 or B7-2), display severely impaired CD4+ T cell
proliferation. The absence of a “second signal” at the time of TCR
ligation leads to the development of T cell anergy, a state charac-
terized by decreased proliferative capacity, the inability to secrete
IL-2 and reduced ability to undergo activation.While positive cos-
timulatory signals promote T cell proliferation and differentiation
into effector phenotypes, negative signals lead to arrest of T cell
responses and promote regulation and tolerance. Therefore, T cell
activation involves a delicate balance betweenpositive andnegative
costimulatory signals.
Solid organ transplantation is a lifesaving therapy for patients
with end-stage organ failure and while short-term allograft sur-
vival has improved dramatically, long-term outcomes remain
disappointingly poor. Current immunosuppressive protocols are
highly effective at suppressing acute rejection but are associated
with signiﬁcant morbidity with long-term use. To date, induction
of donor speciﬁc tolerance has remained an elusive goal for all but
the most aggressive therapeutic strategies, suitable only for a small
subset of patients. Innate mechanisms of regulation and coinhi-
bition are as yet incompletely understood but remain the focus of
intensive research. In targeting our goal of inducing allospeciﬁc
tolerance without global immunosuppression, the most promis-
ing strategies would appear to be those aimed at limiting positive
costimulation, in combination with selective signaling through
inhibitory pathways. However, there are a number of coinhibitory
molecules and substantial overlap exists between these pathways.
Therefore, successful induction of tolerance may require manip-
ulation of more than one to overcome the inherent redundancy
between them. To this end, a detailed understanding of the relative
importance of each negative costimulatory pathway, their expres-
sion patterns, receptors and ligands, and the interactions between
them is crucial to develop coherent strategies to control aggressive
alloimmune responses.
Below, we discuss the current state of knowledge of the most
widely studied negative costimulatory pathways (Figure 1) and
their potential applications in alloimmunity. To provide some
pathophysiological context and highlight the overlap between
pathways observed in disease pathogenesis, we have provided
examples of disease states in which each of these molecules has
been implicated. The examples provided are intended to be illus-
trative only, as a complete description is beyond the scope of
this text.
CTLA-4:B7-1/B7-2
Cytolytic T lymphocyte-associated antigen 4 (CTLA-4) is a mem-
ber of the Ig superfamily and is closely structurally related toCD28,
with which it shares approximately 30% homology. CTLA-4 is
not expressed by naïve T cells but is rapidly upregulated on T
cell activation and CD28 engagement (Walunas et al., 1994). It is
highly expressed on regulatory T (Tregs) cells and is central to their
suppressive function and the maintenance of peripheral tolerance
(Wing et al., 2008).
Cytolytic T lymphocyte-associated antigen 4 is mainly located
within intracellular vesicles (Mead et al., 2005). Upon TCR
ligation, it is trafﬁcked to the cell surface where it forms a
www.frontiersin.org March 2012 | Volume 3 | Article 47 | 1
McGrath and Najaﬁan Negative costimulation and transplantation tolerance
FIGURE 1 | Major negative costimulatory pathways. Associated positive
signaling pathways marked with “+.”
homodimer. However, it appears that CTLA-4 continuously
undergoes endocytosis, where cell surface CTLA-4 is rapidly re-
internalized independent of ligand binding (Linsley et al., 1996).
Its fate after being internalized remains incompletely understood,
but it appears that some molecules are degraded in lysosomes
and some are trafﬁcked back to the cell surface (Linsley et al.,
1996; Egen and Allison, 2002). CTLA-4 shares the same ligands
as CD28; B7-1 (CD80) and B7-2 (CD86), but binds with 10- to
50-fold greater binding afﬁnity.
B7-1 and B7-2 are both widely expressed on B cells,
macrophages,dendritic cells (DCs) andT cells and are rarely found
on non-lymphoid tissues. B7-2 is constitutively expressed on anti-
genpresenting cells (APCs) at low levels and is rapidly upregulated,
whereas B7-1 expression is induced, later than B7-2. While their
function onAPCs has been extensively studied, their role on T cells
is incompletely understood. Recent studies have suggested that B7
on T cells may serve to down-regulate responses and deliver nega-
tive signals to T cells, through CTLA-4 ligation via T-T interaction
(Taylor et al., 2004). B7 deﬁciency on T cells resulted in accelerated
graft versus host disease (GVHD) in a model of allogeneic bone
marrow transplantation (Taylor et al.,2004). Furthermore,B7deﬁ-
cient T cells demonstrate resistance to suppression by Tregs in an
in vivo colitis model (Paust et al., 2004). As discussed below, B7-1
has also been demonstrated to interact with PD-L1, producing a
coinhibitory signal.
More recent data, using receptor array techniques, indicates
that ICOS ligand, B7-H2, is also a costimulatory ligand for CD28,
with a distinct binding site from ICOS. B7-H2 binds both CD28
and CTLA-4, albeit at a lower afﬁnity than B7-1 or B7-2 (Yao et al.,
2011). Furthermore, CD28 binds B7-H2 and B7-1/B7-2 through
different interfaces, potentially allowing simultaneous binding
of these ligands. Interestingly however, Abatacept, (CTLA-4-Ig),
binds B7-H2 and also blocks the interaction between B7-H2-Ig
and CD28, suggesting that CTLA-4 may have a greater afﬁnity
for B7-H2 than CD28 (Yao et al., 2011). In terms of function,
B7-H2 binding to CD28 costimulates T cell proliferation and
appears to play a central role in IFNγ production from mem-
ory T cells. While B7-H2 may act synergistically with B7-1 and
B7-2 to deliver CD28-mediated costimulatory signals, the impact
of B7-H2:CTLA-4 interaction remains largely unstudied. This
link between the ICOS:B7-H2 positive costimulatory pathway
and CTLA-4 is interesting as this could also potentially repre-
sent a regulatory mechanism to control ICOS-induced T cell
activation, However, these data were acquired in vitro and there-
fore the true signiﬁcance of these observations in vivo remains
unknown.
Cytolytic T lymphocyte-associated antigen 4 ligation blocks
T cell activation, inhibits CD28-dependent IL-2 production and
inhibits cell cycle progression (Walunas et al., 1994, 1996). Despite
a large body of literature, there remains considerable ongoing
investigation into its exactmechanismof action.CTLA-4mediated
inhibition of T cell activation is currently thought to arise through
both“cell intrinsic”and“cell extrinsic”mechanisms. Firstly,CTLA-
4 acts as an antagonist of CD28 by competitively binding B7-1
and B7-2, thereby blocking positive costimulatory signaling. This
hypothesis is consistent with the known greater afﬁnity and avidity
of CTLA-4 for these ligands. More recently it has been proposed
that CTLA-4 expression may also increase T cell mobility and
oppose the TCR induced “stop signal” needed for contact between
T cells and APCs, thereby limiting the potential for T cell activa-
tion (Schneider et al., 2006). In addition, through binding B7-1
and B7-2, CTLA-4 blocks transmission of signals from the TCR
by inhibiting the formation of ZAP-70 containing microclusters,
leading to reduced calcium mobilization, which then limits T cell
capacity for proliferation (Schneider et al., 2008). A splice variant
of CTLA-4 has also been described. This variant lacks the extra-
cellular ligand-binding domain and is proposed to constitutively
generate a ligand-independent inhibitory signal (Vijayakrishnan
et al., 2004). The importance of this splice variant in control
of T effector cell responses is suggested by its increased expres-
sion in disease-resistant strains of NOD mice when compared to
diabetes-susceptible congenic strains (Vijayakrishnan et al., 2004;
Araki et al., 2009). However, this splice variant does not appear to
be present in humans and therefore appears unlikely to represent
a central mode of action of CTLA-4 in immunity.
In addition, it has been suggested that CTLA-4 exerts its effect
through “cell extrinsic” mechanisms of immune suppression.
A recent paper elegantly demonstrates the capacity of CTLA-
4 to capture B7-2 and internalize it for degradation; leading to
impaired T cell activation (Qureshi et al., 2011). This process was
diminished through deletion of the cytoplasmic tail of CTLA-4
and through the use of blocking antibodies such as anti-CTLA-4,
but not by blockade of CD28, demonstrating that this mechanism
is speciﬁc toCTLA-4. Furthermore,while transendocytosis of B7-2
by CTLA-4 occurs constitutively, it is upregulated after TCR acti-
vation, providing an explanation for the increased Treg suppressive
activity observed afterT cell activation (Qureshi et al., 2011).Other
cell extrinsic mechanisms of action for CTLA-4 have been pro-
posed including induction of indoleamine 2,3-dioxygenase (IDO)
activity, (thereby leading to localized tryptophan depletion and
decreased T cell proliferation; Munn et al., 1999) and the presence
of a soluble form of CTLA-4, which could locally affect T cell acti-
vation (Magistrelli et al., 1999). However, conﬂicting data exist for
both of these mechanisms and their true signiﬁcance and role in
immunity remains unclear.
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CTLA-4 IN DISEASE STATES
Cytolytic T lymphocyte-associated antigen 4 holds a central role in
the control of T cell responses, as evidencedby the fact thatCTLA-4
deﬁcient mice die at 3–4weeks of age of uncontrolled lymphopro-
liferative disease (Tivol et al., 1995). In humans, CTLA-4 gene
polymorphisms have been implicated in many autoimmune dis-
eases including thyroid disease, type I diabetes mellitus, rheuma-
toid arthritis (RA) and systemic lupus erythematosis (Ueda et al.,
2003). Dysregulation of intracellular expression of CTLA-4 has
been proposed as a cause of the lymphoproliferative disorder,
Chediak–Higashi syndrome (Barrat et al., 1999).
IMPACT OF CTLA-4 ON Treg FUNCTION
The central role of CTLA-4 on Treg function has been demon-
strated in studies where administration of anti-CTLA-4 led to the
development of organ speciﬁc autoimmunity in immune compe-
tent mice, without reducing total Treg numbers (Takahashi et al.,
2000). Furthermore, Tregs from CTLA-4−/− mice exhibit weak
suppressive activity in vitro. This function is independent of CD28
expression as Tregs from CD28 deﬁcient mice show normal sup-
pressive activity (Takahashi et al., 2000). Finally, other studies
suggest that engagement of CTLA-4 may lead to the development
of antigen speciﬁc Tregs, leading to inhibition of T cell responses
in certain experimental models (Vasu et al., 2004).
Recent studies outline the role of reverse signaling through B7-
1 and B7-2 in control of immune responses. Engagement of B7 on
DCs by CTLA-4 initially leads to increased IFNγ, which acts in a
paracrine fashion to increase indoleamine 2,3-dioxygenase (IDO)
thereby inhibiting T cell proliferation (Grohmann et al., 2002; Fal-
larino et al., 2003). As Tregs highly express CTLA-4, a mechanism
of Treg suppression has been proposed where IDO production by
B7 expressing DCs appears to act as an important bridge between
Tregs and naïve responder cells (Mellor et al., 2004). The impor-
tance of this pathway in vivo is underpinned by data from amurine
model of islet transplantation, where inhibition of IDO abrogated
the graft prolonging effects of CTLA-4-Ig (Grohmann et al., 2002).
CTLA-4 IN MODELS OF TRANSPLANTATION
Cytolytic T lymphocyte-associated antigen 4-Ig is a fusion pro-
tein,which avidly binds B7, thereby competitively inhibitingCD28
costimulation. This antibody has been used to study the effects of
costimulation blockade in experimental models of skin, heart, and
kidney transplantation. Administration of CTLA-4-Ig on day 2
after renal or cardiac transplantation lead to improved allograft
survival, decreased pro-inﬂammatory cytokine production and
decreased histological evidence of chronic allograft vasculopathy
when compared with treatment with cyclosporine alone (Azuma
et al., 1996; Russell et al., 1996).When donor speciﬁc transfusion at
the time of transplantation was combined with CTLA-4-Ig, long-
term graft survival with donor speciﬁc tolerance was seen (Lin
et al., 1993). Treatment of murine recipients of xenogeneic pan-
creatic islets with CTLA-4-Ig at the time of transplant similarly
led to prolonged allograft survival and donor speciﬁc tolerance
(Lenschow et al., 1992). Finally, combined with CD40 blockade,
treatment with CTLA-4-Ig has been demonstrated to lead to long-
term allograft survival in both cardiac and a highly immunogenic
skin transplant model (Larsen et al., 1996).
Interestingly, delayed treatment with CTLA-4-Ig, administered
8weeks after transplantation, lead to decreased progression of
chronic allograft rejection with attenuation of cardiac allograft
vasculopathy (Chandraker et al., 1998). This suggests that ongo-
ing T cell recognition of foreign antigen is an important mediator
of late allograft injury and costimulation blockade, even given
late after transplantation, may delay progression. Similar results
were seen in a study where an anti-CTLA-4 blocking antibody was
given at various timepoints, up to 30 days after cardiac transplan-
tation. Immediate rejection was not seen but instead treatment led
to delayed severe acute cellular rejection at approximately day 45
post transplant, again indicating the active role of CTLA-4 in the
maintenance of tolerance post transplantation (Chandraker et al.,
2005).
Administration of CTLA-4-Ig in CD28 deﬁcient transplant
recipients leads to accelerated allograft rejection compared to wild
type. In this model of cardiac transplantation, similar accelera-
tion of rejection was observed after treatment with a blocking
anti-CTLA-4 antibody, demonstrating that the negative regulatory
function of CTLA-4 extends beyond its ability to competitively
inhibit CD28 signals (Lin et al., 1998).
More recent studies have examined the link between CTLA-4
expression and CD45 mediated allograft tolerance. Anti-CD45RB
is a potent immunomodulatory agent and has been shown to
induce donor speciﬁc tolerance in models of renal and islet trans-
plantation (Lazarovits et al., 1996). Interestingly, administration
of anti-CD45RB is associated with rapid upregulation of CTLA-4
expression in vivo. Blockade of CTLA-4 at the time of islet trans-
plantation abrogated the graft prolonging effect of anti-CD45RB,
demonstrating the dependence of this pathway on CTLA-4
induction to promote allograft survival (Fecteau et al., 2001).
CTLA-4 IN HUMAN STUDIES OF TRANSPLANTATION
Genetic studies suggest that polymorphisms in CTLA-4 are asso-
ciated with differing incidence of acute allograft rejection. In a
cohort of over 200 liver transplant patients, single nucleotide
polymorphisms (SNPs) previously linked with decreased CTLA-4
function were found to be more common in patients with shorter
allograft survival (Marder et al., 2003). Similarly, a study of Korean
kidney transplant recipients linked the sameSNPwith an increased
risk of late acute allograft rejection (Kim et al., 2010).
BELATACEPT IN KIDNEY TRANSPLANTATION
Initial attempts to generate an antibody to blockCD28were unsuc-
cessful, as the majority of antibodies generated lead to signaling
rather than blockade of this pathway. As described above, CTLA-
4-Ig, the ﬁrst antibody developed to successfully block CD28:B7
interactions, is a recombinant fusion protein comprising the Fc
domain of human IgG1 linked to the extra-cellular portion of
CTLA-4 (Vincenti et al., 2011). CTLA-4-Ig, known commercially
as Abatacept, was licensed for clinically for the treatment of RA.
However, it proved ineffective in non-human primate studies of
transplantation and the molecule was re-engineered, leading to
the generation of Belatacept. Belatacept differs from Abatacept
by two amino acid substitutions at the ligand-binding domain
and binds B7-1 and B7-2 with greater avidity, thereby producing
greater immunosuppressive effects (Vincenti et al., 2011).
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Phase III human trials in kidney transplant recipients have
demonstrated similar graft survival in those treated with Belata-
cept versus cyclosporine, despite increased rates of acute rejection
in the early post transplant period (Vincenti et al., 2010). At 3 year
follow up, patients treated with Belatacept showed better renal
function, with higher mean eGFR and lower rates of donor spe-
ciﬁc antibody formation (Vincenti et al., 2012). On the basis of
these studies, Belatacept was approved by the FDA in June 2011,
for the prevention of acute rejection post renal transplant.
However, despite the early success of Belatacept in transplan-
tation, there remains some concern as to the overall impact of
blocking CD28 signaling through competitive antibody binding
to B7. This strategy also blocks the ability of CTLA-4 to bind
B7-1 and -2 and in particular, this may negatively impact on the
development of antigen speciﬁc Tregs (Vasu et al., 2004) and on the
function of existingTregs, possibly blocking their suppressive activ-
ity. Indeed, a recently published study reported that treatmentwith
CTLA-4-Ig prolonged survival in a fullymismatchedmodel of car-
diac rejection but precipitated accelerated rejection in a partially
mismatched model, where engraftment is dependent upon Treg
function (Riella et al., 2012). Furthermore, intactCTLA-4 function
has also previously been shown to be critical for the maintenance
of graft tolerance in a model of induced tolerance in skin trans-
plantation (Markees et al., 1998). These issues may provide some
explanation as to why CTLA-4-Ig does not reproducibly induce
tolerance in certain models of transplantation. Alternative agents
currently under investigation include anti-CD28antibodies,which
selectively block CD28 without impacting CTLA-4 function. Tar-
geting the CD28/CTLA-4: B7-H1/2 pathway in this manner may
instead promote Treg function and has generated some promis-
ing data in non-human primate studies of renal transplantation
(Poirier et al., 2010).
CONCLUSIONS
CD28 is the most important T cell costimulatory molecule and
CTLA-4 holds a central role in the control of CD28-mediated
immune responses, including alloimmune responses. Data from
human studies indicate that blockade of this pathway using Belat-
acept should prove to be a useful addition to treatment protocols
post kidney transplantation. It is hoped that the advent of cos-
timulation blockade will reduce the severity of chronic allograft
rejection both through control of immune mediated injury, and
through decreased exposure to calcineurin inhibitors, both of
which contribute to reduced long-term renal allograft survival.
However, several important issues remain unanswered.
Increased rates of early acute rejection were observed in clinical
trials of Belatacept. While these episodes were responsive to ther-
apy, the long-term impact of these episodes of early acute rejection
on allograft survival are as yet unclear. Furthermore, the nature of
the T cell response and whether it relates to blockade of CTLA-
4 mediated suppression of T effector cells remain unknown. It
is also unclear if CTLA-4-Ig blocks the recently described coin-
hibitory interaction between B7 and PD-L1 (described below)
and how biologically signiﬁcant this will prove to be in complex
models of alloimmunity. Finally, some data suggests that CTLA-
4:B7 interaction may inhibit differentiation of pro-inﬂammatory
Th17 cells and that blockade of CTLA-4 exacerbates Th17-driven
experimental autoimmune encephalitis (EAE; Ying et al., 2010).
Further studies are needed to explore these issues in detail, to
understand the complex interactions between CD28 and CTLA-
4 and their links with other costimulatory and coinhibitory
pathways in vivo.
PD-1: PD-L1/PD-L2; PD-L1: B7-1
PD-1 is a type I transmembrane protein and is a member of the
immunoglobulin superfamily. Its intracellular domain contains an
immunoreceptor tyrosine-based inhibitorymotif (ITIM)aswell as
an immunoreceptor tyrosine-based switch motif (ITSM; Okazaki
et al., 2001). In humans andmice, it is expressed on activated T and
B cells and myeloid cells. Its two ligands, PD-L1 and PD-L2, show
differential expression patterns. PD-L1 is constitutively expressed
on all haematopoietic cells and many non-haematopoietic tissues
and is upregulated after activation whereas PD-L2 is inducibly
expressed on DCs and macrophages only. Upon ligand engage-
ment, PD-1 is phosphorylated and recruits SHP-1 and -2 to the
antigen-receptor complex (Okazaki et al., 2001).
PD-1 signaling inhibits PI3k activity (Parry et al., 2005), leading
to decreased T cell proliferation, reduced IFNγ and IL-2 produc-
tion and increased T cell apoptosis (Sandner et al., 2005). Using
multi-photon laser-scanning microscopy techniques to study the
movement of T cells in vivo, Fife et al. described the mechanism
of inhibition of T cell activation induced by PD-1:PD-L1 signal-
ing. In this model, T cell activation was decreased by blocking
the TCR-induced stop signal, thereby maintaining T cell mobil-
ity within lymph nodes and decreasing interactions between T
cells and antigen bearing DCs (Fife et al., 2009). Of note, PD-1
mediated inhibition depends upon the strength of TCR ligation,
with greatest inhibition delivered at low levels of TCR stimulation.
Furthermore, this inhibition can be overcome by stronger costim-
ulatory signals, such as those delivered through CD28 (Freeman
et al., 2000).
PD-1 IN DISEASE STATES
PD-1 plays an important role in the maintenance of self-tolerance
and its deﬁciency leads to varying disease states depending upon
the genetic background of the animals studied. PD-1−/− on
a Balb/c background suffer from autoimmune cardiomyopathy
while C57BL/6 PD-1−/− develop progressive arthritis and a lupus-
like glomerulonephritis (Fife and Bluestone, 2008). Furthermore,
PD-1 blockade and deﬁciency in NOD mice leads to accelerated
autoimmune diabetes (Ansari et al., 2003; Wang et al., 2005a) and
PD-1 blockade leads to the development of accelerated and clin-
ically more severe EAE in mouse models (Salama et al., 2003).
Of note, PD-L1 has been implicated in the development of T
cell exhaustion (Urbani et al., 2006; further discussed below) and
its tissue expression also plays a crucial role in the maintenance
of peripheral tolerance (Keir et al., 2006). Similar to other coin-
hibitorymolecules, polymorphisms in PD-1 have been linkedwith
a range of autoimmune conditions in humans, including MS, SLE,
Type I DM, and Grave’s disease (Keir et al., 2008).
IMPACT OF PD-1 ON Treg FUNCTION
Regulatory T cells upregulate PD-1 expression on activation (Rai-
mondi et al., 2006) and blockade of PD-1 appears to decrease
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the suppressive activity of Tregs in vivo (Kitazawa et al., 2007).
Furthermore, in the setting of transplantation, PD-L1 blockade
appears to alter the balance of Tregs/Teffector cells and promote
aggressive alloresponses (Sandner et al., 2005).
PD-1:PD-L1/PD-L2 IN MODELS OF TRANSPLANTATION
In keeping with its role as a negative costimulatory pathway,
blockade of PD-1 leads to accelerated allograft rejection in fully
mismatched cardiac allografts.However,partiallymismatched car-
diac transplants survive long-term inPD-1 deﬁcient recipients (Ito
et al., 2005; Tao et al., 2005). This discrepancy suggests that PD-
1 signals play a greater role in disease models where CD4+ and
CD8+ T cell-dependent responses are prominent. More detailed
studies have demonstrated that blockade of PD-L1 speciﬁcally, but
not PD-L2, was associated with accelerated rejection in skin and
cardiac allograft models, characterized by increased proliferation
and decreased apoptosis of allospeciﬁc CD4+ T cells (Barrat et al.,
1999; Sandner et al., 2005; Yang et al., 2008).
Administration of a fusion protein which is agonistic for PD-
1, PD-L1-Ig, has been demonstrated to prolong cardiac allo-
graft survival in both CD28−/− recipients and, when given with
cyclosporine, WT recipients of full mismatched cardiac allo-
grafts. This survival was associated with decreased IFNγ expres-
sion and reduction in pro-inﬂammatory cytokine production
(Ozkaynak et al., 2002). Furthermore, PD-L1-Ig synergizes with
anti-CD154mAb to promote long-term islet allograft survival
(Gao et al., 2003). Finally, intact PD-1:PD-L1 signaling has been
reported to be central to the spontaneous tolerance in murine liver
allografts (Morita et al., 2010).
In a further layer of complexity, tissue expression of PD-1
ligands appears to play an important role in allograft outcome.
Donor, but not recipient, PD-L1 deﬁciency is associated with an
increased tempo of cardiac allograft rejection; characterized by
accelerated chronic allograft vasculopathy, greater frequency of
effector T cells and increased IFNγ production (Yang et al., 2008).
Studies using bone marrow chimeras have demonstrated that tol-
erance induced by CTLA-4-Ig is dependent upon the presence of
PD-L1 on donor endothelium (Riella et al., 2011). Mechanistic
studies showed increased pro-inﬂammatory cytokine production
and increased CD8+ effector/memory T cell frequency in recipi-
ents of grafts lacking PD-L1 endothelial expression (Riella et al.,
2011). Furthermore, the effect of PD-1 pathway appears to differ
between cell types. In a GVHD model, blockade of PD-L2 but not
PD-L1 lead to increased proliferation of allospeciﬁc CD8+ T cells
with little effect of CD4+ T cells (Habicht et al., 2007). Differing
PD-1 ligand expression in a lymphoreplete versus a lymphopenic
model may also inﬂuence these observations.
Recently, B7-1 has been recognized as an alternative binding
partner for PD-L1, albeit at lower afﬁnity than for PD-1 (Butte
et al., 2007). This interaction also transmits a coinhibitory sig-
nal leading to decreased T cell proliferation, reduced cytokine
production and reduction in activation marker expression. In
a MHC Class II mismatched model of chronic cardiac allograft
rejection, PD-L1 blockade accelerated rejection in B7-2, but not
B7-1, deﬁcient recipients (Yang et al., 2011). Moreover, adminis-
tration of an antibody which speciﬁcally blocked the B7-1:PD-L1
interaction led to more severe chronic allograft vasculopathy with
upregulation of pro-inﬂammatory cytokines and reduction in
splenic Tregs (Yang et al., 2011). These data demonstrate the rele-
vance of this interaction using in vivo models of transplantation
and are of particular relevance in light of the recent availability
of the costimulation blocker, Belatacept, in clinical practice. The
impact of Belatacept on the interaction between B7-1 and PD-L1
is unknown and may be an important area of future investigation.
PD-1 PATHWAY IN HUMAN STUDIES OF TRANSPLANTATION
Preliminary studies have looked at the predictive value of uri-
nary levels of PD-1, PD-L1, and PD-L2 mRNA in the diagnosis
of acute allograft rejection in human recipients. Elevated urinary
PD-1 mRNA, was associated with biopsy proven acute rejection
and when measured in combination with urinary mRNA for
OX40,OX40L, and Foxp3, was a strong predictor of acute allograft
rejection (Afaneh et al., 2010).
In human transplant recipients, the role of allograft tissue
expressionof PD-1 and its ligands have also been examined. PD-L1
is expressed on human renal tubular epithelial cells and has been
reported to suppress alloreactive T cell responses (Starke et al.,
2010). Furthermore, while these molecules are not seen on native
kidneys, immunohistochemical staining of renal allograft sam-
ples revealed induction of PD-1, PD-L1, and PD-L2 in rejecting
allografts. No correlation was seen between staining and serum
creatinine or proteinuria. However, the expression of PD-L1 was
signiﬁcantly higher in those grafts showing vascular (Banff 2a and
2b) versus tubulointerstitial rejection (Banff 1a and 1b; Starke
et al., 2010).
CONCLUSIONS
The differential expression of ligands for CTLA-4 and PD-1 has
lead to hypotheses that these negative costimulatory pathways
occupy non-redundant roles in control of immune responses.
CTLA-4 may control early T cell activation, whereas PD-1 may be
more important in control of later stages and in particular T cell
activation within the transplanted organ. Therefore, these path-
ways appear to play complementary roles in alloimmunity and
robust strategies to promote tolerance may involve targeting both.
Data from human studies suggest that PD-1 and PD-L1 may
be useful biomarkers for non-invasive diagnosis of allograft rejec-
tion, most likely in combination with a panel of other molecules.
More importantly, animal models have demonstrated that tissue
expression of PD-1 and its ligands play an important role in mod-
ulating the alloresponse to the graft. Furthermore, upregulation of
these molecules is seen in rejecting grafts, in murine and human
studies, perhaps in response to local tissue injury. Whether this is
associated with limitation of the alloresponse or possibly a marker
of greater responsiveness to therapy, is as yet unknown, and will
form an important area of future investigation. Finally, an exciting
prospect exists that manipulation of graft expression of these mol-
ecules, either through targeted gene therapy or the use of drugs
to upregulate expression,may promote a tolerogenic environment
and inﬂuence graft survival.
B7-H3
B7-H3 is a member of the B7 family of costimulatory molecules.
It is a type-1 transmembrane protein with a short cytoplasmic tail
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and no known signaling domain. It is broadly expressed in human
tissues and in the immune system, its expression is induced on
monocytes, DCs, and T cells upon activation (Chapoval et al.,
2001). This wide pattern of expression suggests B7-H3 may have
diverse immunological and non-immunological functions. In
keeping with this, its exact role in immunity remains unclear, with
positive and negative costimulatory functions being reported. Ini-
tial studies of human B7-H3 using a B7-H3-Ig fusion protein,
suggested it was a positive costimulatory molecule, demonstrating
increased T cell proliferation, IFNγ production and CTL gener-
ation (Chapoval et al., 2001). Its receptor is found on activated
T cells and is distinct from CD28, CTLA-4, ICOS, and PD-1
(Chapoval et al., 2001).
Triggering receptor expressed on myeloid cells (TREM)-like
transcript 2 (TLT-2) has been proposed as a receptor for B7-
H3 (Hashiguchi et al., 2008). TLT-2 is constitutively expressed on
CD8+ T cells and is induced on CD4+ T cells after activation. In
this study, B7-H3:TLT-2 was reported to enhance T cell responses
in vitro, with modest increases IL-2 and IFN-γ production on
CD4+ and CD8+ T cells seen after TLT-2 and B7-H3 interac-
tion (Hashiguchi et al., 2008). However, a more recent paper has
strongly refuted these ﬁndings, and reports no interaction between
B7-H3 and TLT-2 on murine or human cells (Leitner et al., 2009).
Inmice,B7-H3 is constitutively expressed onprofessionalAPCs
and a small population of splenic T cells. Its expression is increased
onDCs after incubationwith LPS (Prasad et al., 2004). Contrary to
the human study, data from murine studies using a blocking anti-
body against B7-H3 demonstrate its role as a negative regulator of
T cell activation (Prasad et al., 2004). An agonistic fusion protein,
B7-H3-Ig, was found to markedly decrease proliferation, IL-2 and
IFNγ production by T cells incubated with aCD3 (Suh et al., 2003;
Prasad et al., 2004; Leitner et al., 2009). Furthermore, when T cells
were activated with aCD3 in the presence of B7-H3-Ig, reduced
activity of NF-κB, NFAT, and inhibition of AP-1 activation were
observed (Prasad et al., 2004). The effect of B7-H3 signaling was
overcome with CD28-mediated costimulation, suggesting B7-H3
may exert greatest effect in situations where CD28 costimulation
is limited. In addition, use of a blocking mAb, anti-B7-H3, lead to
greatly enhanced T cell proliferation (Prasad et al., 2004). Unlike
the human data, murine studies did not conﬁrm a role for B7-H3
in CTL responses in vitro or in vivo (Suh et al., 2003).
B7-H3 IN DISEASE STATES
In vivo, treatment with an antagonistic mAb, anti-B7-H3, lead to
earlier onset of EAE, more clinically severe disease and greater
numbers of brain-inﬁltrating CD4+ T cells in treated than con-
trols (Prasad et al., 2004). Finally, B7-H3 deﬁcient APCs show
greater costimulatory capacity than wild type (Suh et al., 2003).
In a murine model of airway inﬂammation, B7-H3 deﬁcient
mice developed more severe airway inﬂammation and increased
T cell inﬁltration than controls in Th1 but not Th2 conditions
(Suh et al., 2003). Furthermore, B7-H3 expression on DCs was
enhanced by IFNγ but suppressed by IL-4. Taken together, these
data suggest a role for B7-H3 in negative regulation of T cell
responses occurring under Th1 polarizing conditions.
Extensive studies of B7-H3 function in cancer biology have
also revealed contradictory data. In several mouse cancer models,
ectopic overexpression of B7-H3 leads to activation of tumor spe-
ciﬁc CTLs and slowed growth or tumor eradication (Hofmeyer
et al., 2008). However, human studies in non-small cell, prostate
and ovarian cancers have shown increased disease severity where
malignant cells showed increased B7-H3 expression, suggesting
B7-H3may be acting as an immune evasion pathway in this setting
(Hofmeyer et al., 2008).
B7-H3 IN MODELS OF TRANSPLANTATION
The role of B7-H3 in transplantation has not yet been extensively
studied but again, conﬂicting data exists. Using a complete MHC
mismatched cardiac allograft model, prolonged allograft sur-
vival was seen in B7-H3−/− recipients treated with Cyclosporine
or Rapamycin (Wang et al., 2005b). Analysis of graft inﬁltrat-
ing cells revealed decreased expression of both cytokines IL-2
and IFN-γ and chemoattractant proteins MCP-1 and IP-10 in
treated B7-H3−/− recipients compared with control animals. No
differences were seen in expression of regulatory cytokines (Wang
et al., 2005b). Chronic allograft rejection was investigated using
two models; a complete MHC mismatched allograft combined
with anti-CD154 treatment and a Class II mismatched cardiac
transplant. Decreased chronic allograft vasculopathy with similar
cytokine expression proﬁles were observed in B7-H3−/− recipients
in both models.
In contrast however, our group has extensive preliminary data
demonstrating the role of B7-H3 as a negative regulator of alloim-
munity. B7-H3−/− recipients show attenuated allograft survival
and treatmentwith an agonistic fusion protein,B7-H3-Ig prolongs
allograft survival in a complete MHC mismatch model (Ueno,
Yeung, personal communication).
The differing effects observed between these transplantation
studies may possibly relate to speciﬁcs of the individual B7-
H3 knockouts described and also the binding afﬁnity/functional
activity of fusion proteins studied. Furthermore, the existence of
separate “costimulatory” and“coinhibitory” ligands for B7-H3 has
not yet been excluded. The contradictory ﬁndings suggest the role
played by B7-H3 varies, dependent upon the system being stud-
ied. Furthermore, B7-H3 has wide tissue expression and little is
known as to its local activity in regulating immunity. Clearly, fur-
ther detailed studies are required to elucidate the exact role of
B7-H3 in alloimmunity and its relative importance as a potential
therapeutic target.
B7-H4
B7-H4 is a type I transmembrane protein and is a recently
described member of the B7 family. While B7-H4 mRNA is found
in a variety of tissues, it is not expressed on naïve T cells, B cells
or DCs. Its expression is upregulated after in vitro stimulation of
human T cells, B cells, monocytes, and DCs (Prasad et al., 2003;
Sica et al., 2003). Its receptor, as yet unidentiﬁed, is thought to
be expressed on activated T cells and appears to be distinct from
known CD28 family members. Finally, it has also been shown to
suppress neutrophil-mediated immune processes, thereby playing
a role in innate immunity (Zhu et al., 2009).
In studies using an agonistic fusion protein,B7-H4was demon-
strated to inhibit T cell proliferation both in vitro and in vivo
(Prasad et al., 2003; Sica et al., 2003). Signaling through B7-H4
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lead to suppression of IL-2 and IFN-γ production in vitro. In
addition, there appears to be an interaction between B7-H4 and
Treg function. In a model of GVHD, treatment with B7-H4-Ig sup-
pressed the generation of CTLs both in vitro and in vivo (Sica et al.,
2003). In vitro studies suggest that suppressive function of APCs
is associated with increased B7-H4 expression. This appears to be
mediated through Treg production of IL-10 (Kryczek et al., 2006).
Finally, blockade of B7-H4 lead to accelerated onset and worsen-
ing severity of murine EAE, further indicating its important role
in control of T cell responses (Prasad et al., 2003).
B7-H4 IN DISEASE STATES
Early treatmentwithB7-H4-Ig reduced the incidenceof diabetes in
NOD mice, associated with reduced insulitis scores and increased
pancreatic inﬁltration with Foxp3+ CD4+ T cells in treated mice
(Wang et al., 2011). In a similar vein, B7-H4 was overexpressed
on an insulinoma cell line transplanted into C57BL/6 mice with
Streptozotocin-induced diabetes. Improved survival was observed
in the B7-H4 group; this was associated with an increased splenic
Treg population and reciprocally reduced IFN-γ-producing and
increased IL-4 producing splenocytes (Yuan et al., 2009). Another
group found that B7-H4 overexpression promoted islet allograft
survival and induced donor speciﬁc tolerance (Wang et al., 2009a).
Similar to studies of B7-H3 in cancer biology, B7-H4 appears
to play a role in tumor immune evasion. It appears to be highly
expressed on human tumors including breast, lung, prostate, and
ovarian malignancies. In keeping with its known role as a negative
regulator of immune responses, the presence of B7-H4 positive
cells has been repeatedly shown to correlate with reduced num-
bers of tumor inﬁltrating lymphocytes and worse outcomes (Yi
and Chen, 2009).
B7-H4 IN MODELS OF TRANSPLANTATION
A small number of studies have addressed the role of B7-H4
in alloimmunity. Our group has recently described the effect of
B7-H4 blockade in murine model of cardiac transplantation. In
a fully mismatched cardiac allograft model, blockade of B7-H4
did not affect allograft survival. However B7-H4 blockade signiﬁ-
cantly accelerated allograft rejection in CD28−/− recipients and in
CD80/CD86DKO recipients, in whom fully mismatched allografts
usually survive long-term(Yamaura et al., 2010). This rejectionwas
accompanied by increased frequency of IFN-γ and IL-4 producing
splenocytes and increased levels of donor speciﬁc antibodies. Fur-
thermore, blockade of this pathway with anti-B7-H4 precipitated
acute rejection in mice treated with CTL-A4-Ig where long-term
allograft acceptance is the norm (Yamaura et al., 2010).
These data suggest that B7-H4 plays a dominant negative reg-
ulatory role in controlling alloreactive T cells in the absence of
CD28/CTLA-4:B7 signaling. In this fashion, it appears to play a
non-redundant role in ﬁne-tuning the immune response in vivo.
Although not yet fully elucidated, this role may prove of increasing
relevance going forward; particularly where costimulatory block-
ade using agents such as Belatacept becomes increasingly common
in clinical practice.
BTLA/CD160/LIGHT:HVEM
This complex pathway involves a number of players, the most
widely studied of which are B and T cell lymphocyte attenuator
(BTLA), herpesvirus entry mediator (HVEM), and LIGHT. These
threemolecules interact directly with each other but it appears that
HVEMoccupies a central role and can direct either positive or neg-
ative costimulatory signals depending upon its receptor binding.
Central to understanding the role of this pathway in immunity is
an analysis of the complex interactions and relative roles of each
of the molecules involved.
B and T cell lymphocyte attenuator is a member of the Ig super-
family and shares structural homology with PD-1 and CTLA-4.
BTLA is a type I membrane glycoprotein with a single C-type Ig
domain and three conserved tyrosine motifs in its cytoplasmic tail;
two of which a found within (ITIMs; Watanabe et al., 2003). As
predicted by its structure, BTLA acts as a negative costimulatory
molecule. Binding to its ligand, HVEM, induces phosphorylation
of its ITIM domain. This is followed by association with SH2
domain-containing protein tyrosine phosphatase 1 (SHP-1) and
SHP-2, leading to attenuation of signals promoting cellular acti-
vation and growth (Sedy et al., 2005). It is broadly expressed
across cells of both innate and adaptive immunity and is found
on CD4+ and CD8+ T cells, B lymphocytes, DCs, NK cells, and
also endothelial cells.
B and T cell lymphocyte attenuator expression is low on naïve
CD4+ T cells (10–15%; Tao et al., 2008) but increases with anti-
gen speciﬁc stimulation and peaks on day 2 (Hurchla et al.,
2005). This declines by day 7 but secondary reactivation of T
cells leads to rapid BTLA induction (Hurchla et al., 2005). In
terms of T cell subsets; greater expression is seen on Th1 than
Th2 cells (Hurchla et al., 2005) and little is expressed on Tregs.
In addition, BTLA is highly expressed on anergic CD4+ T cells
in vivo (Hurchla et al., 2005). The highest levels of BTLA expres-
sion on T cells were seen with anergy induction (Hurchla et al.,
2005). BTLA deﬁcient T cells proliferate more vigorously than
wild type when stimulated with aCD3 or APCs. This appears to
be primarily due to increased CD8+ T cell proliferation. Further-
more, BTLA−/− CD8+ T cells are more efﬁcient at differentiating
into memory T cells than WT cells (Krieg et al., 2005). This
is thought to explain the higher proportion of memory T cells
observed in both BTLA−/− and HVEM−/− animals (Krieg et al.,
2005).
B and T cell lymphocyte attenuator is unique among coin-
hibitory members of the Ig superfamily, in that it binds to HVEM,
which is a member of the TNF receptor superfamily. Other lig-
ands for HVEM have been described, including CD160, which
also transduces a negative costimulatory signal (Cai et al., 2008).
HVEM also binds the canonical TNF ligands, LTα (Murphy and
Murphy, 2010; lymphotoxin alpha), and LIGHT (Mauri et al.,
1998; lymphotoxin-like, exhibits inducible expression, and com-
petes with herpes simplex virus glycoprotein D for HVEM, a
receptor expressed by T lymphocytes) both of which are posi-
tive costimulatory molecules. HVEM engagement with BTLA and
CD160 both activate inhibitory signaling in lymphocytes (Sedy
et al., 2005; Murphy et al., 2006; Cai et al., 2008). BTLA and
CD160 both bind to the N-terminal membrane distal cysteine-
rich domain-1 (CRD-1) of HVEM (Sedy et al., 2005), whereas the
positive costimulatory molecules, LIGHT and LTα, bind to CRD-2
and CRD-3 (Rooney et al., 2000). LTα has not yet been studied in
alloimmunity and will not be discussed further here.
www.frontiersin.org March 2012 | Volume 3 | Article 47 | 7
McGrath and Najaﬁan Negative costimulation and transplantation tolerance
Herpesvirus entry mediator is widely expressed across cells of
innate and adaptive immunity and is also found on endothelial
cells. However, its relative role in differing cell subsets remains
unclear. Signaling through HVEM activates NF-kB, and in this
manner it costimulates B cell proliferation and immunoglobulin
secretion (Duhen et al., 2004) and on DCs (Salio et al., 1999), NK
cells (Kwon et al., 1997) and non-haematopoietic cells, it promotes
activation of effector functions (Marsters et al., 1997). During T
cell activation, HVEM shows a reciprocal expression pattern to
BTLA, with high HVEM expression seen on naive CD4+ which
markedly decreases with T cell activation (Morel et al., 2000). This
returns to high levels as CD4+ cells become quiescent.
LIGHT is expressedonmonocytes, granulocytes, and immature
DCs (Tamada et al., 2000). LIGHT expression on peripheral blood
lymphocytes is induced with TCR activation but it is constitutively
expressed on CD4+ cells and NK cells in mucosal tissues. (Cohavy
et al., 2005) LIGHT does not itself appear to have signaling motifs
but it shows potent CD28 independent costimulatory activity. Its
interaction with HVEM provides a positive costimulatory signal
(Sedy et al., 2005) leading to increased MAP kinase activity, T cell
activation (Shi et al., 2002), and increased inﬂammatory responses
(Ware, 2008).
LIGHT exists in both membrane-bound and soluble forms,
cleaved by matrix metalloproteases. Interestingly, binding of
LIGHT appears to modulate the interaction between BTLA and
HVEM and its effect on this interaction varies greatly dependent
upon the form. As described above, LIGHT has a separate binding
site to BTLA on HVEM (Rooney et al., 2000) and its binding, in
soluble or membrane-bound forms to HVEM, modulates the sig-
nal produced when BTLA binds, providing a tight feedback loop.
Both membrane-bound and soluble LIGHT can induce NF-κB
activation through HVEM but membrane-bound LIGHT shows
much more robust activity than the soluble form (Cheung et al.,
2009). Conversely, membrane-bound LIGHT non-competitively
disrupts binding between BTLA and HVEM (Cheung et al., 2005).
The regulation of LIGHT cleavage in vivo has not yet been eluci-
dated but it appears to play an important role in determining the
downstream effect of BTLA:HVEM interaction.
CD160 is the second coinhibitory molecule involved in this
pathway. It binds HVEM and inhibits CD4+ proliferation and
cytokine production (Cai et al., 2008). CD160 is highly expressed
on human NK cell subsets, CD8+ T cells, NKT cells, γδ T cells,
and on all intestinal intra-epithelial T lymphocytes (IELs; Maeda
et al., 2005). However, functional studies of CD160 have not been
reported to date and little is known about its role in auto- or allo-
immunity in vivo. Although both act to control T cell proliferation,
CD160 andBTLAappear to showdistinct expressionpatterns, sug-
gesting their inhibitory functions may be non-overlapping in vivo.
BTLA PROMOTES T CELL SURVIVAL
Aside from its role as coinhibitory molecule, there are data to sug-
gest BTLA also promotes T cell survival. In vitro data using an
NF-κB reporter shows that BTLA binding to HVEM leads to NF-
κB activation and promotes cell survival (Cheung et al., 2009).
Furthermore, the presence of soluble LIGHT increased the avidity
of BTLA binding to HVEM and augmented the observed NF-κB
activation.
BTLA−/− T cells fail to sustain GVHD in a non-irradiated
GVHD model. BTLA−/− T cells show normal expansion initially
after adoptive transfer,but failed to sustain inﬂammation (Hurchla
et al., 2007). After the ﬁrst week, BTLA−/− T cells show a sharp
decline in effector cell numbers, which is accompanied by reso-
lution of GVHD (Hurchla et al., 2007). Furthermore, BTLA−/−
T cells fail to elicit a strong anti-host response as demonstrated
by lack of depletion of host B cells. Similar ﬁndings were seen
with antibody blockade of BTLA on wild type cells. Mechanistic
studies showed that these T cells show decreased proliferation and
decreased cytolytic activity (Hurchla et al., 2007).
IMPACT OF BTLA:HVEM ON Treg FUNCTION
The expression of BTLA is low on Tregs and BTLA−/− Tregs
demonstrate normal suppressive activity (Tao et al., 2008). Upon
activation, T effector cells express increased BTLA but markedly
down-regulate HVEM. In contrast, activated Tregs strongly upreg-
ulate HVEM but not BTLA. The importance of this pathway in
Treg function is emphasized by ﬁndings that HVEM−/− Tregs show
decreased suppressive activity andWT Tregs are unable to suppress
BTLA−/− T effector cells (Tao et al., 2008). In addition, studies
using fully mismatched cardiac allografts suggest that long-term
allograft survival could not be achieved in the absence of HVEM
on Tregs (Tao et al., 2008). While HVEM does not appear to be
a dominant functional pathway on Tregs (as HVEM−/− mice do
not display spontaneous autoimmunity observed in Foxp3 deﬁ-
cient mice), these data suggest a potentially important role in
alloimmunity, which requires further detailed evaluation.
BTLA:HVEM IN DISEASE STATES
BTLA−/− mice are more prone to develop autoantibodies and
develop a hepatitis-like syndrome with advancing age (Oya et al.,
2008). Expansion of CD4+ and NKT cell populations in the liver
parenchyma with associated endothelialitis and portal inﬂamma-
tion has also been described (Oya et al., 2008). BTLA−/− also show
greater allergic airway inﬂammation (Deppong et al., 2006) and
greater susceptibility to EAE (Greenwald et al., 2005). HVEM−/−
mice show increased susceptibility to Con A mitogen induced,
autoimmune hepatitis (Wang et al., 2005c). LIGHT−/− mice show
impaired T cell responses (Tamada et al., 2000).
In amurinemodel of inﬂammatory bowel disease,Rag−/− mice
developedmore severe colitis upon adoptive transfer of HVEM−/−
T cells compared to transfer of wild type T cells. Transfer for
BTLA−/− cells did not accelerate colitis in the same fashion (Stein-
berg et al., 2008). It has been proposed that this may be due to lack
of T cell survival as observed in the GVHD model described above
(Hurchla et al., 2007). Treatment of HVEM−/− Rag−/− recipients
with a BTLA agonist reversed the observed colitis (Steinberg et al.,
2008). These data suggest BTLA:HVEM plays an important role in
control of effector T cell responses in vivo. Furthermore, data from
Rag−/− studies suggests the negative costimulatory effect of BTLA
signaling may be the more dominant pathway regulating in vivo
immune responses, rather than positive costimulation mediated
through LIGHT.
A Taiwanese study of 94 patients with RA reported an associ-
ation between a SNP [C(+800)] in BTLA and increased risk of
RA. This SNP is located in the region between the two ITIMs
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in the cytoplasmic tail of BTLA (Lin et al., 2006). In addition, a
small Japanese study showed an association between a different
BTLA SNP (590C) and RA, but not with SLE or Sjogren’s syn-
drome. In this study, patients bearing this SNP were reported to
have presented with disease earlier than those without (Oki et al.,
2011). The functional consequences of either of these SNPs remain
unknown.
BTLA IN MODELS OF TRANSPLANTATION
Several studies have described prolonged islet cell allograft survival
after treatment with anti-BTLA antibodies. One such antibody,
PJ196, given in combination with CTLA-4-Ig, has been reported
to lead to long-term islet cell allograft survival (Truong et al.,
2007a). The mechanism of action of this antibody is unclear.
BTLA expressing cells were not depleted, but BTLA surface expres-
sion was markedly down-regulated after treatment with PJ196.
Furthermore, earlier data had suggested this antibody does not
simply act as a BTLA agonist as it did not decrease in vitro T
cell proliferation. After combination treatment with CTLA-4-Ig,
islet graft histology demonstrated massive cellular inﬁltration,
primarily consisting of CD4+ Foxp3+ Tregs. Such inﬁltrate was
not observed after treatment with anti-BTLA alone, leading the
authors to speculate that combined treatment may have enhanced
the local milieu for Treg generation, possibly through down-
regulating coinhibitory signals on Tregs and thereby enhancing
their function (Truong et al., 2007a).
In a related publication from the same group, treatment with
a depleting anti-BTLA antibody, 6F7, alone led to modest non-
signiﬁcant prolongation of islet allograft survival, when compared
with control. No graft prolongation was seen in BTLA−/− recip-
ients and addition of CTLA-4-Ig did not signiﬁcantly prolong
allograft survival in BTLA−/− mice. Combination of anti-BTLA
(6F7) with CTLA-4-Ig again lead to long-term islet allograft sur-
vival in thismodel (Truong et al., 2007b). Treatmentwas associated
with a reduction in total T cell, CD4+ cell and B cell number.
Furthermore, the percentage of CD4+ cells expressing PD-1 was
signiﬁcantly increased in the anti-BTLA treatment group.
As seen in the earlier study, allograft histology demonstrated
local accumulation of CD4+ Foxp3+ cells in tolerant animals.
In vivo donor speciﬁc tolerance was present and third party
grafts were appropriately rejected. However, in vitro studies
showed no difference in T cell proliferation or cytolytic killing
in response to allogeneic stimulus in tolerant mice. In vivo CFSE
proliferation studies conﬁrmed that 6F7 does not show signif-
icant impact on proliferation of allogeneic CD4+ or CD8+ T
cells (Truong et al., 2007b). The function of this mAb in vivo
is unclear, but the lack of effect on proliferation of activated
T cells suggests that similar to PJ196, 6F7 is not simply an
agonistic antibody. Through an unclear mechanism, increased
expression of PD-1 was observed along with increased local
Treg accumulation in the treated animals. It is unclear if anti-
BTLA mAb acts to increase PD-1 expression either directly or
if this occurs through indirect mechanisms by blocking BTLA
signaling.
Further studies have examined the role of BTLA in the survival
of Class I or Class II mismatched cardiac allograft survival. In con-
trast to wild type recipients, where partially mismatched cardiac
allografts survive long-term, both BTLA−/− and HVEM−/− recip-
ients rejected their grafts within 4weeks of transplantation. Treat-
ment with a blocking anti-BTLA mAb (6A6) led to accelerated
rejection, at a similar tempo (Tao et al., 2005).
While targeting PD-1 did not induce acute rejection in this
model, recipients deﬁcient in both BTLA and PD-1 rejected their
allografts, at a slightly faster tempo than BTLA−/− alone. More-
over, targeting BTLA via any one of either BTLA−/−, HVEM−/−
recipients,or administrationof a blocking anti-BTLAmAb,all lead
to accelerated allograft rejection in amismatchedmodel (Tao et al.,
2005). Similarly, T cell alloreactivity was greatly enhanced in the
absence of BTLA or HVEM. While BTLA was induced on allore-
active T cells post partially mismatched cardiac transplantation,
PD-1 was not.
Interestingly, and unexpectedly, in the setting of transplan-
tation across a full MHC mismatch, T cells from BTLA−/−
mice display decreased proliferation and cytokine production and
these recipients show slightly prolonged cardiac allograft sur-
vival. As discussed previously (in PD-1 section), following fully
mismatched cardiac transplantation; PD-1 expression is greatly
increased on CD4+ and CD8+ alloreactive T cells. Unexpectedly,
this increase in expression is more marked in BTLA−/− recipi-
ents. Treatment with anti-PD-1 blockade or transplantation into
a BTLA/PD-1 double knockout recipient abrogated this effect and
led to acute allograft rejection, similar to controls (Tao et al.,
2005).
Based on the above data, it appears that BTLA signaling plays
an important role in the maintenance of tolerance to partially
mismatched cardiac allografts, a well-studied model of chronic
rejection. However, in the setting of stronger alloimmune stimu-
lus, as seen with fully mismatched transplantation, the impact of
BTLA on allograft tolerance is much less. In these circumstances,
the pro-tolerogenic effect of PD-1 appears to be dominant. Again,
the effect of targeting BTLA on induction of PD-1 expression
remains unclear, but these data suggest an important link between
these two negative costimulatory pathways.
The differences in survival in the cardiac and islet transplant
data possibly relate to the antibodies used. The cardiac transplants
were carried out using a non-depleting, blocking anti-BTLA mAb
(6A6) whereas the islet cell transplants used a depleting antibody
(6F7) or one that down-regulated BTLA expression (PJ196).
Several groups have studied the role of BTLA using GVHD
models. Using a parent into non-irradiated F1 murine model of
GVH, treatment with an antagonistic anti-BTLA mAb (4G12b)
was shown to decrease anti-host response in terms of inﬁltration
of bone marrow and thymus along with a marked reduction in
the cytotoxic T cell activity (Del Rio et al., 2011). Further stud-
ies have shown that anti-BTLA mAb (6A6), administered at the
timeof allogeneic hematopoietic stemcell transplantation (HSCT)
prevented the development of GVHD (Albring et al., 2010). How-
ever, once GVHD was established, treatment with 6A6 could not
reverse the disease. In this model, lymphocyte depletion was not
seen and the effect was dependent on the presence of BTLA on
donor cells. Overall, treatment at the time of transplantation
appeared to rebalance the T cell expansion in these recipients,
with decreased effector T cell populations, greater proportions of
Tregs with increased Treg/Teff ratio (Albring et al., 2010).
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Finally, a recently published study used an agonistic BTLA
mAb (BYK-1), which does not block the interaction of BTLA and
HVEM.Administration of thismAbprofoundly inhibited the gen-
eration of donor anti-host CTLs (Sakoda et al., 2011). Similar to
the study using 6A6 mAb, treatment at the time of transplantation
prevented the development of GVHD in recipient mice and led
to long-term survival and successful engraftment (Sakoda et al.,
2011). These effects were shown to be dependent on donor T
cells and additionally, T cell-expressed BTLA was demonstrated
to deliver a pro-survival signal, through HVEM (Sakoda et al.,
2011). Taken together, these data suggest BTLA blockade may be a
potential therapeutic target in HSCT to prevent the development
of GVHD while allowing survival and engraftment of donor cells.
CONCLUSIONS
Attempts to dissect and understand this pathway are complicated
by several major issues. These include the number of binding
partners for HVEM, their varied functions, and the fact that
most lymphoid cells can express any of these receptors/ligands
(BTLA, HVEM, LIGHT, and CD160) at differing stages of their
development and activation. However, active regulation of HVEM
expression appears to be a central tenet to controlling its interac-
tions with BTLA, CD160, and LIGHT. As such, HVEM appears to
occupy a central role, acting as a molecular switch, to direct T cell
activation in an inhibitory or stimulatory direction.
The observed bidirectional signaling through BTLA:HVEM,
the effect of LIGHT on their interaction and the relative expres-
sion of these molecules are all issues that need to be considered
when interpreting disease or transplantation models involving
this pathway. Studies using differing models suggest that the
dominance of one signal over the other varies according to the
type of immune response involved. Some studies suggest that
the positive costimulatory signal through HVEM may predom-
inate in pathogenesis of GVHD, where blockade of BTLA has
led to impaired allogeneic responses and HVEM−/− mice suf-
fer less severe GVHD. Meanwhile, in models of autoimmunity
and inﬂammatory responses, BTLA negative costimulatory signal
appears dominant, as BTLA−/− mice show greater susceptibility to
these conditions. However, the impact of LIGHT modulating the
BTLA–HVEM interaction has not yet been adequately investigated
in vivo and remains an important area of future investigation. Fur-
thermore, the link between this pathway and PD-1 remains to be
elucidated.
Further research in this area is crucial to clarify the roles of
these molecules and understand their hierarchy of importance in
models of transplantation. Theoretically, blockade LIGHT:HVEM
costimulation is desirable, as is promotion of coinhibition through
BTLA:HVEMsignaling.However, recent data highlighting the cos-
timulatory effect of BTLA binding to HVEM, leading to increased
NF-κBactivation andpro-survival signals, soundanote of caution.
Therefore, the development of antibodies binding BTLA to pro-
mote its signaling rather than HVEM may prove the most promis-
ing target. In vivo data from models of transplantation appear to
indicate that those antibodies that deplete or down-regulate BTLA
expression are more effective in controlling alloresponses. How-
ever,much work remains to be done to develop our understanding
of this pathway as a potential therapeutic target.
TIM-3:GALECTIN-9
The T cell immunoglobulin mucin (TIM) family members are a
novel group of costimulatory molecules, expressed on a wide vari-
ety of innate and adaptive immune cells. While TIM-3 is present
on predominantly on Th1 cells, it is found on Th17 cells at lower
levels and is also expressed on CD8+ T cells, DCs, macrophages,
and mast cells (Freeman et al. (2010)). In studies using an antag-
onistic TIM-3Ig fusion protein, TIM-3 blockade in naïve CD4+
cells was demonstrated to increase proliferation and increase IFNγ
production (Sabatos et al., 2003). Galectin-9, an S type lectin, is
the ligand for TIM-3. It is expressed on Tregs, B cells, and mast cells
and is also found on non-immune cells such as endothelial cells
and ﬁbroblasts (Zhu et al., 2005).
Upon binding galectin-9, the intracellular tail of TIM-3 is phos-
phorylated by the interleukin inducible T cell kinase (ITK; van de
Weyer et al., 2006), leading to intracellular calcium inﬂux and
apoptosis. TIM-3 signaling is thought to be a critical inhibitory
mechanism whereby Th1 responses are controlled. Furthermore,
IFNγ upregulates galectin-9 expression, leading to an elegant feed-
back loop (Kashio et al., 2003; Zhu et al., 2005). Similarly, admin-
istration of soluble galectin-9 decreases Th17 differentiation (Seki
et al., 2008) while blockade of TIM-3 increases IL-17 production
(Hastings et al., 2009; Boenisch et al., 2010), demonstrating the
role of this pathway in controlling Th17 responses.
Data on the role of TIM-3 signaling in innate immunity are
conﬂicting. Interruption of signaling during induction of EAE
leads to macrophage expansion and activation resulting in a more
severe clinical phenotype (Monney et al., 2002). Similarly, TIM-3
blockade during liver ischemia–reperfusion injury increases neu-
trophil inﬁltration, cytokine release, and hepatocyte apoptosis
(Uchida et al., 2010). In contrast, ex vivo studies suggest TIM-3
acts synergistically with TLR stimuli to increase pro-inﬂammatory
TNF-α secretion from DCs, which may in turn promote T effector
responses (Anderson et al., 2007).
TIM-3 IN MODELS OF TRANSPLANTATION
Galectin-9 is expressed on Tregs and studies demonstrate that
blockade of TIM-3:galectin-9 reduces the suppressive activity of
Tregs in vitro. In vivo TIM-3 blockade at the time of transplantation
abrogates the tolerizing effect of donor derived Treg transfusion,
leading to accelerated graft loss when compared with controls
(Wang et al., 2009b). Similarly, in a model of islet transplant
tolerance induced with DST and anti-CD154, TIM-3 blockade
was associated with loss of tolerance and rapid allograft rejection
(Sanchez-Fueyo et al., 2003) and TIM-3 interactions have been
demonstrated to be essential for the generation of donor speciﬁc
Tregs (Sanchez-Fueyo et al., 2003).
TIM-3:galectin-9 interactions appear to be central to Treg func-
tion and tolerance induction. Galectin-9 expression on T cells is
limited solely to Tregs (Sabatos et al., 2003; Wang et al., 2009b).
TIM-3 blockade abrogates induced peripheral tolerance, causes
signiﬁcant attenuation of suppressive activity of natural Tregs and
increased auto- and allo-immune responses including autoanti-
body production (Sabatos et al., 2003; Muthukumarana et al.,
2008; Wang et al., 2009b). Furthermore, TIM-3 signaling appears
to facilitate the acquisition of donor speciﬁc tolerance; TIM-3 deﬁ-
cient mice are refractory to tolerance induction (Sabatos et al.,
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2003) and the generation of allospeciﬁc Tregs during tolerance
induction has been demonstrated to be dependent upon intact
TIM-3:galectin-9 pathway (Sabatos et al., 2003; Sanchez-Fueyo
et al., 2003). In a murine model of islet cell transplantation, toler-
ant allografts displayed blunted intra-graft expression of TIM-
3 and IFN-γ as compared with rejected grafts (Sabatos et al.,
2003).
In fact, TIM-3 broadly modulates the alloresponse in vivo. In
a fully mismatched model of chronic cardiac allograft rejection,
accelerated graft loss is observed with TIM-3 blockade (Boenisch
et al., 2010). This rejection is characterized by increased donor
speciﬁc alloantibody production, increased Th1 and Th17 polar-
ization, and suppression of adaptive Treg induction (Boenisch
et al., 2010). Administration of exogenous stable galectin-9 has
been used to promote TIM-3 signaling in experimental models.
Treatment has been associated with prolonged allograft survival of
both skin and cardiac allografts (Wang et al., 2008; He et al., 2009).
These studies used models of both acute and chronic allograft
rejection, and all consistently demonstrated that TIM-3:galectin-9
interaction leads to Th1 and Th17 suppression while promoting
Treg differentiation (Wang et al., 2008; He et al., 2009).
TIM-3 IN HUMAN TRANSPLANT RECIPIENTS
In human transplant recipients, TIM-3 may be helpful as a bio-
marker of Th1 activation and rejection. Small studies indicate that
TIM-3 mRNA levels are signiﬁcantly higher within rejecting allo-
grafts and that there is a strong correlation between intra-graft
TIM-3 and IFN-γ levels. Interestingly, treatment-refractory rejec-
tion episodes showed relatively lower levels of TIM-3, suggesting a
link between lack of negative costimulatory signaling and poorer
allograft outcomes (Ponciano et al., 2007). In addition, measure-
ment of TIM-3 mRNA in urine and blood have proved accurate
in the differentiation of delayed graft function (DGF) with acute
tubular necrosis versus DGF with acute rejection (Manfro et al.,
2008). Patients with acute rejection showed much higher urine
TIM-3 mRNA levels than those with other causes of allograft
dysfunction or non-rejecting controls (Renesto et al., 2007; Man-
fro et al., 2008). While larger studies will be needed to validate
these ﬁndings, these data suggest potential utility of TIM-3 mRNA
measurement as a non-invasive tool in the diagnosis of allograft
dysfunction.
OTHER FUNCTIONS OF TIM-3
TIM-3 also functions as a phosphatidylserine receptor and medi-
ates phagocytosis of apoptotic cells (Nakayama et al., 2009).
Blockade of this phagocytic capacity has been shown to promote
autoantibody production and impair cross presentation by CD8+
DCs (Nakayama et al., 2009). As discussed in greater detail below,
increased TIM-3 expression on CD8+ T cells has been associated
with an exhausted phenotype, with decreased viral clearance and
reduced anti-tumor immunity (Golden-Mason et al., 2009;Meng-
shol et al., 2010; Sehrawat et al., 2010). The mechanisms involved,
including the role of galectin-9 in these conditions, remain unclear
at this time.
CONCLUSIONS
Taken together, experimental data indicate that TIM-3:galectin-
9 plays a central role in regulation of Th1 responses including
alloimmune responses. Through signaling on Tregs, TIM-3 is
involved in the generation of antigen speciﬁc tolerance. Admin-
istration of galectin-9 has promoted allograft survival in both a
stringent skin graft model and a vascularized model of transplan-
tation. Human studies correlate TIM-3 levels with alloimmune
activation and risk of rejection. These data indicate that targeting
this pathway pharmacologically may hold signiﬁcant promise in
the management of detrimental alloresponses (Wang et al., 2008;
He et al., 2009). However, several important issues remain to be
clariﬁed. In particular, the impact of targeting TIM-3 on phagocy-
tosis of apoptotic bodies and maintenance of peripheral tolerance,
and the relative importance of galectin-9 expression on donor and
recipient tissues in modulating the immune response, are unclear.
Furthermore, galectin-9 may also function through other, as yet
unidentiﬁed, receptors on T cells, which may contribute to the
observed effects (Zhu et al., 2005; Bi et al., 2008).
T CELL EXHAUSTION, NEGATIVE COSTIMULATION, AND
TRANSPLANTATION
T cell exhaustion is a state of T cell dysfunction characterized by
progressive loss of proliferative and effector functions, culminat-
ing in clonal deletion (Virgin et al., 2009). It is most commonly
seen in chronic viral infections and malignancies and is thought
to relate to chronic antigenic stimulation (Wherry et al., 2003).
There appears to be a link between the strength of antigenic stim-
ulation and degree of T cell exhaustion, where larger amounts of
epitopes lead to more severe degrees of exhaustion, even with sim-
ilar viral loads. To date, it has been most widely studied in CD8+
T cells but is also thought to affect CD4+ T cells. Immune regula-
tion is central to T cell exhaustion and expression of coinhibitory
molecules appears to be a crucial feature. Exhausted T cells dis-
play high expression of PD-1 (Barber et al., 2006) but increased
CD160, TIM-3, and CTLA-4 expression have all been described
on virus-speciﬁc CD8+ T cells in chronic infection (Crawford
and Wherry, 2009). Furthermore, studies from the cancer litera-
ture have reported reversal of T cell exhaustion through blockade
of TIM-3 and PD-1 signaling (Sakuishi et al., 2010).
The role of T cell exhaustion in solid organ transplantation
has not yet been widely studied. Several groups have reported
on the impact of alloantigen load on alloreactive CD8+ T cells
and demonstrated evidence of T cell exhaustion with decreased
proliferative capacity and reduced effector cytokine production
(Quezada et al., 2003; Steger et al., 2008). However, the expres-
sion of coinhibitory molecules was not examined in these stud-
ies. The true impact of T cell exhaustion on allograft outcomes
remains unclear and whether manipulation of negative costimu-
latory pathways could lead to exhaustion of speciﬁc alloreactive
T cell clones is unknown but is a fascinating potential research
avenue.
SUMMARY AND FUTURE DIRECTIONS
With widespread expression across immune cells and tissues, neg-
ative costimulatory molecules are an appealing target for allospe-
ciﬁc tolerance induction. An increasing body of literature outlines
the complexity of these pathways, involving variable expression
of receptors and ligands but also overlapping functions and
interactions of different pathways.
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In terms of hierarchy of costimulatory molecules, CD28 occu-
pies a central role in T cell activation and therefore in opposing
this, CTLA-4 is considered the most important coinhibitory mol-
ecule. CTLA-4-Ig blocks CD28-mediated costimulation through
competitive binding to B7, but does not consistently induce allo-
graft tolerance across varied transplant models. This observation
is thought to be due to the presence of other positive costim-
ulatory pathways unaffected by CTLA-4-Ig, but also may rep-
resent inadvertent blockade of tolerogenic CTLA-4 signals. To
begin to address this issue, several groups are currently work-
ing on antibodies which can block CD28 speciﬁcally, without
affecting CTLA-4 function. Recent non-human primate studies
of transplantation using a novel anti-CD28 appear to hold some
promise in this area. However, there is likely to be a require-
ment for concomitant negative costimulatory signals to induce
robust allospeciﬁc tolerance. A more complete understanding of
the mechanisms of action of CTLA-4, as provided by recent land-
mark studies, will help to inform and guide further investigation
in this area.
Studies of the PD-1 pathways have greatly advanced our under-
standing of costimulation and the importance of tissue-expressed
ligands in T cell activation and directing the alloresponse. Anti-
body blockade of both PD-1 and PD-L1 has been shown to accel-
erate allograft rejection, associated with increased proliferation of
allospeciﬁc CD4+ T cells. Prolonged allograft survival is seen after
administration of a PD-1 agonist in the setting of CD28 deﬁciency;
suggesting that this may be a promising therapy to combine with
blockade of CD28. Tissue expression of PD-L1 also appears to
play an important role in directing the alloresponse, as indicated
by data showing donor PD-L1 deﬁciency leads to accelerated allo-
graft rejection and tolerance induced by CTLA-4-Ig appears to be
dependent on PD-L1 on donor endothelium.
B7-H3 and B7-H4 have not been extensively investigated in
alloimmunity but current data suggests these may play an impor-
tant role in ﬁne-tuning the immune responses in the setting of
limited CD28-mediated stimulation. In particular, B7-H3 appears
to negatively regulate T cell responses under Th1 polarizing con-
ditions and manipulation of this pathway may prove useful to
prevent rejection, a predominantly Th1 mediated process. How-
ever, as described above, the current data is conﬂicting and these
ﬁndings need to be resolved to fully assess the role of B7-H3 in
alloimmunity. In addition to negative costimulation, B7-H4 also
appears to promote Treg function by increasing IL-10 production.
B7-H4 may also prove a useful pathway to target, as adjunctive
therapy with CD28 blockade.
Furthermore, there is broad similarity in the expression of B7-
H3, B7-H4, PDL-1, and PDL-2 in lymphoid and non-lymphoid
tissues, and their receptors are all expressed on activated T cells.
These features suggest a role for these molecules in regulating
activation of naïve T cells in lymphoid tissue and effector T cell
function in the periphery. Signals transmitted by these B7 ligands
may be tissue speciﬁc and regulated by inﬂammatory cytokines;
thereby inﬂuencing the nature and extent of T cell function. Ther-
apeutic strategies aimed atmanipulating expression of or signaling
through these molecules locally either within the graft or drain-
ing lymph nodes may be important future avenues to promote
allospeciﬁc tolerance without systemic immunosuppression.
Through limiting the development of GVHD and promot-
ing engraftment, manipulation of BTLA signaling may prove an
important strategy in the management of stem cell transplanta-
tion. Thedata from islet cell transplantation is also quite promising
but these models do not address the complex interactions with
other ligands such as LIGHT. Of particular interest, there appears
to be interaction between BTLA and PD-1 in the induction of tol-
erance. BTLA−/− mice show greater induction of PD-1 expression
and improved allograft survival, in a PD-1 dependent manner.
This relationship warrants further exploration and may prove a
useful link between these coinhibitory pathways. However, the
complex interactions between the different molecules involved in
BTLA:HVEM signaling and the potential for bidirectional signal-
ing, render this a challenging pathway to exploit. At this time,
much remains to be understood before any potential agent could
be brought closer to clinical applications.
TIM-3 and its ligand, galectin-9, are exciting new players in
the ﬁeld of coinhibition. Recent data demonstrates the ability of
TIM-3 to broadlymodulate the immune response.Administration
of galectin-9 has been demonstrated to prolong allograft sur-
vival with decreases in Th1 and Th17 alloimmunity and increased
allospeciﬁc Treg generation. Furthermore, TIM-3 blockade has
been shown to prevent tolerance induction. These data suggest
a central role for TIM-3 in regulation of tolerance and that pro-
motion of TIM-3 signaling, perhaps through administration of
exogenous stable galectin-9, may prove an additional important
tool in the quest to induce tolerance in transplant recipients.
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